NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors.
Several extracellular matrix (ECM) molecules have been identified as potent inhibitors of neurite outgrowth in vitro and are believed to limit axonal growth after CNS injury. Recent studies have shown that different members of the chondroitin sulfate proteoglycan (CSPG) class of putatively inhibitory ECM molecules are expressed after a number of CNS injuries. The purpose of this study was to evaluate the relative amounts of individual CSPGs expressed after spinal cord injury (SCI) and identify their cells of origin. Evaluation of total soluble CSPGs 2 weeks after dorsal column lesion in the rat demonstrated that NG2 is highly upregulated and is a major CSPG species. Immunocytochemical analysis further demonstrated that NG2 expression is upregulated within 24 hr of injury, peaks at 1 week, and remains elevated for at least an additional 7 weeks. NG2 expression results from a multicellular response to injury, including both reactive macrophages and oligodendrocyte progenitors; astrocytes were not identified as a major source of NG2. Immunocytochemical analysis of other CSPG family members 7 d after injury showed moderate upregulation of versican, brevican, and neurocan, and downregulation of phosphacan. Axonal tracing experiments demonstrated dense NG2 labeling adjacent to the forward processes of transected corticospinal tract axons in a spatial profile that could restrict axonal growth. Thus, NG2 is a major component of this putatively inhibitory class of ECM molecules expressed at sites of SCI and may restrict axonal regeneration.
Jones
Leonard L
LL
Department of Neurosciences, University of California, San Diego, La Jolla, California 92093, USA.
Yamaguchi
Yu
Y
Stallcup
William B
WB
Tuszynski
Mark H
MH
D000818:Animals; D000941:Antigens / Q000378:metabolism*; D001253:Astrocytes / Q000473:pathology; D001369:Axons / Q000378:metabolism / Q000473:pathology; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D015151:Immunoblotting; D007150:Immunohistochemistry; D008264:Macrophages / Q000378:metabolism* / Q000473:pathology; D017628:Microglia / Q000473:pathology; D009836:Oligodendroglia / Q000166:cytology; D011509:Proteoglycans / Q000378:metabolism*; D051381:Rats; D011916:Rats, Inbred F344; D016622:Silver Staining; D013119:Spinal Cord Injuries / Q000378:metabolism* / Q000473:pathology; D013234:Stem Cells / Q000378:metabolism* / Q000473:pathology; D000099216:Chondroitin Sulfate Proteoglycan 4
D000941:Antigens; D011508:Chondroitin Sulfate Proteoglycans; D011509:Proteoglycans; D000099216:Chondroitin Sulfate Proteoglycan 4